Tesamorelin

Tesamorelin is a stabilised synthetic analog of endogenous growth hormone-releasing hormone (GHRH), comprising the complete 44-amino acid sequence of native GHRH with the addition of a trans-3-hexenoic acid moiety covalently attached to the N-terminus. This chemical modification is not cosmetic — it is the pharmacological key that transforms tesamorelin from a fragile, rapidly degraded peptide into a stable, clinically useful compound. The target of the modification is dipeptidyl peptidase IV (DPP-IV), an enzyme abundantly expressed in plasma, kidney, and intestinal brush border that cleaves the first two amino acids from the N-terminus of GHRH and several other peptide hormones, rapidly inactivating them. DPP-IV is the same enzyme that degrades the incretin hormones GLP-1 and GIP, and DPP-IV inhibitors (gliptins) are an approved class of diabetes drugs. By blocking DPP-IV cleavage of the tesamorelin N-terminus, the trans-3-hexenoic acid modification extends tesamorelin's effective half-life and potency to a degree that makes it both a superior GHRH stimulator compared to shorter analogs like sermorelin and a clinically viable therapeutic agent.

Tesamorelin received FDA approval in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. This was a landmark regulatory achievement: the first FDA approval of a GHRH analog for any adult indication, and the first approval of any peptide specifically targeting visceral adiposity. The medical need was real and compelling: antiretroviral therapy (ART), while transformative in reducing HIV morbidity and mortality, is associated in many patients with lipodystrophy — a syndrome characterised by peripheral fat atrophy (lipoatrophy from the face, limbs, and buttocks) combined with central visceral fat accumulation. This visceral fat accumulation in HIV patients receiving ART is associated with increased cardiovascular risk, metabolic syndrome, insulin resistance, and significant physical and psychological distress. Prior to tesamorelin's approval, no effective medical treatment existed for HIV-associated central adiposity.

The pivotal Phase 3 clinical trials for tesamorelin demonstrated a 15–17% reduction in trunk visceral adipose tissue (VAT) measured by CT scan at 26 weeks, compared to placebo — a clinically significant and objectively measurable reduction in the metabolically dangerous visceral depot. Secondary outcomes confirmed improvements in the VAT:SAT ratio (visceral to subcutaneous adipose tissue), reductions in triglycerides (a direct metabolic consequence of GH-driven lipolysis), and improvements in quality of life and patient-reported outcomes. The effect was sustained at 52 weeks in completers and reversed over several months when treatment was discontinued, confirming that the VAT reduction represents an ongoing pharmacological effect that requires continued treatment to maintain.

Beyond its FDA-approved indication, tesamorelin has attracted substantial research interest based on a notable 2018 randomised controlled trial (Fairman et al., published in JAMA Neurology) that found tesamorelin significantly improved executive function and verbal memory in older HIV-negative adults over 20 weeks, independent of its body composition effects. This finding was remarkable because it identified a cognitive benefit from GH axis stimulation in non-HIV adults with age-related GH decline — raising the possibility that tesamorelin-driven IGF-1 elevation supports brain function via IGF-1 receptors in hippocampal and prefrontal neurons. Follow-up work from the same group has explored tesamorelin's potential to reduce brain amyloid burden and cognitive decline in older adults, positioning it as a candidate intervention at the intersection of metabolic and neurocognitive ageing.

Comparing tesamorelin to sermorelin in terms of potency: tesamorelin's DPP-IV resistance and complete 44-amino acid GHRH sequence make it a more potent and longer-acting GHRH signal than sermorelin (GHRH 1-29), producing larger IGF-1 elevations per unit dose. However, like sermorelin, tesamorelin's GH-stimulating effects remain subject to physiological negative feedback from IGF-1 — it cannot drive the GH/IGF-1 axis to unphysiological extremes because the pituitary's own feedback-regulatory mechanisms impose a ceiling. This safety feature is absent with exogenous recombinant GH.

The elevated glucose concern with tesamorelin is mechanistically straightforward and clinically meaningful: GH is a counter-regulatory hormone that opposes insulin's glucose-lowering action. Elevated GH levels (whether from natural secretion or pharmacological stimulation) reduce insulin sensitivity, increase hepatic glucose output, and can raise fasting glucose in susceptible individuals — particularly those with pre-existing insulin resistance, metabolic syndrome, or impaired fasting glucose. This does not mean tesamorelin is inappropriate in these populations, but it does mean that glucose monitoring (fasting glucose and, where appropriate, HbA1c) is a necessary component of any tesamorelin research protocol. In some subjects, the metabolic benefit of visceral fat reduction — which independently improves insulin sensitivity — may offset the direct counter-regulatory effect of GH, resulting in minimal net glucose change. However, this balance is individual and must be monitored rather than assumed.